Abstract Objectives To assess anti-TNF-α therapy response in uveitis associated with sarcoidosis refractory to conventional immunosuppressive therapy. Methods Open-label, multicenter, retrospective ...study on patients with sarcoid uveitis who underwent anti-TNF-α therapy because of inadequate response to conventional therapy including corticosteroids and at least 1 systemic synthetic immunosuppressive drug. The main outcome measurements were degree of anterior and posterior chamber inflammation, visual acuity, macular thickness, and immunosuppression load. Results A total of 17 patients (8 men; 29 affected eyes; mean ± standard deviation age 38.4 ± 16.8; range: 13−76 years) were studied. The patients had bilateral hilar lymphadenopathy (58.8%), lung parenchyma involvement (47.1%), peripheral lymph nodes (41.2%), and involvement of other organs (52.9%). Angiotensin-converting enzyme was elevated in 58.8%. The most frequent ocular pattern was bilateral chronic relapsing panuveitis. The first biologic agent used was adalimumab in 10 (58.8%) and infliximab in 7 (41.2%) cases. Infliximab 5 mg/kg intravenously every 4−8 weeks and adalimumab 40 mg subcutaneously every 2 weeks were the most common administration patterns. In most cases anti-TNF-α therapy was given in combination with immunosuppressive drugs. The mean duration of follow-up was 33.9 ± 17.1 months. Significant improvement was observed following anti-TNF-α therapy. Baseline results versus results at 2 years from the onset of biologic therapy were the following: the median of cells in the ocular anterior chamber (interquartile range — IQR) 0.5 (0−2) versus 0 (0−0) ( p = 0.003), vitritis 0 (0−1.25) versus 0 (0−0) ( p = 0.008), macular thickness (391.1 ± 58.8 versus 247 ± 40.5 µm) ( p = 0.028), and visual acuity 0.60 ± 0.33 versus 0.74 ± 0.27; p = 0.009. The median daily (interquartile range) dose of prednisone was also reduced from 10 (0−30) mg at the onset of the anti-TNF-α therapy to 0 (0−0) mg at 2 years ( p = 0.02). Significant reduction was also achieved in the immunosuppressive load. Conclusion Anti-TNF-α therapy is effective in sarcoid uveitis patients refractory to conventional immunosuppressive therapy. Infliximab and adalimumab allowed a substantial reduction in prednisone dose despite having failed standard therapy.
An old disease in an atypical place Pelegrín, Laura, MD, PhD; Adán, Alfredo, MD, PhD; López-Guillermo, Armando, MD ...
Survey of ophthalmology,
11/2014, Letnik:
59, Številka:
6
Journal Article
Recenzirano
Abstract A 72-year-old man presented with signs on uveítis. Biopsy of an iris lesion established the diagnosis of uveal MALT lymphoma with presumed choroidal involvement.
Abstract Objective The purpose of this report is to present the diagnosis of familial amyloid polyneuropathy (FAP) based on vitreous biopsy and to demonstrate immunohistochemical images of ...transthyretin amyloid protein from vitreous samples. Design Retrospective case series. Methods Retrospective review of clinical charts of patients with FAP who underwent vitrectomy for vitreous opacities and had immunostaining performed on the vitreous specimens. Participants Three patients were selected for the study: 2 patients had already been diagnosed with FAP, and in 1 of the patients the vitreous sample served to establish the diagnosis of FAP. Results Pathology examination of the vitreous specimens confirmed the presence of amyloid with positive Congo red staining, and transthyretin was identified with immunolabeling techniques. In this report, we present immunohistochemical staining images of transthyretin deposits in the vitreous tissues. Conclusions Transthyretin amyloidosis is usually confirmed with positive Congo red staining for amyloid identified by biopsy of peripheral nerves, salivary glands, or abdominal fat. Ocular manifestation of FAP typically appears years after the onset of the disease, and therefore eye tissue specimens usually are not subject to diagnostic biopsies or transthyretin identification. However, in patients with negative systemic tissue biopsies or early ocular involvement, transthyretin identification from samples obtained during vitrectomy may be useful in establishing the diagnosis, and we present the first immunohistochemical images of transthyretin amyloid of vitreous origin, which confirm the elevated deposition of the altered protein in ocular tissues in FAP.
Abstract Objective To assess the 3-year visual outcome of intravitreal bevacizumab in inflammatory ocular neovascularization. Design Experimental study. Methods Retrospective multicenter consecutive ...case series in 81 patients with inflammatory ocular neovascularization refractory to standard therapy and treated with intravitreal bevacizumab. The outcome measures included improvement of best corrected visual acuity expressed as logarithm of minimum angle of resolution (logMAR) and paired comparison decrease in central foveal thickness by optical coherence tomography. Results Mean best corrected visual acuity improved from baseline 0.699 (6/30 or 20/101) (SD 0.434) to 0.426 (6/16 or 20/53) (SD 0.428) (n = 81; p < 0.001), a gain of 2.7 lines (median 3 injections; 81 eyes; 81 patients). Paired comparisons revealed significant central foveal flattening at 3 years of 97.9 μm (n = 51; p < 0.001). In a subgroup analysis, visual improvement was significant for ocular histoplasmosis ( p = 0.026); multifocal choroiditis ( p = 0.05); serpiginous choroiditis ( p = 0.028); ocular toxoplasmosis ( p = 0.042); and punctate inner choroidopathy ( p = 0.015). In a subgroup analysis, foveal flattening was significant for ocular histoplasmosis ( p = 0.004); multifocal choroiditis ( p = 0.007); serpiginous choroiditis ( p = 0.011); and punctate inner choroidopathy ( p = 0.001). Of the group, 5 eyes developed submacular fibrosis, 1 eye retinal pigment epithelial tear, and 1 eye macular ischemia in the context of vasculitis. Conclusion At 3 years, intravitreal bevacizumab sustained significant visual improvement of 2.7 lines and significant foveal flattening of 98 μm in a wide variety of inflammatory ocular diseases without major complications after a median of 3 injections.
